Skip to main content
TipRanks
Go Ultimate75% OFF

Precision BioSciences (DTIL) AI Stock Analysis

848 Followers
DTIL

Precision BioSciences

(NASDAQ:DTIL)

Select Model
Rating:54Neutral
Price Target:$7.00â–¼(-1.41% Downside)
Action:reiterated
Date:11/10/26

The score is held back primarily by weak financial performance—large ongoing losses and substantial negative operating/free cash flow—despite a relatively low-debt balance sheet. Technicals add support due to strong upside momentum, but overbought indicators temper that strength. Corporate events are a net positive given fresh financing and encouraging clinical updates, while valuation is difficult to support with a negative P/E and no dividend yield provided.

Positive Factors
Low balance-sheet leverageVery low leverage gives Precision BioSciences greater financial flexibility than a heavily indebted biotechnology company. The meaningful equity base and minimal debt burden can help preserve resources for clinical development, although continued losses remain an important constraint on that flexibility.
Negative Factors
Persistent unprofitabilityDeeply negative profitability shows that the current business has not yet converted research and development activity into sustainable earnings. Continued losses can erode the equity base over time and increase dependence on successful clinical execution, partnerships, or additional financing.

Precision BioSciences (DTIL) vs. SPDR S&P 500 ETF (SPY)

-50%-25%0%25%50%75%100%125%DTIL+39.22%SPY+11.99%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$198.34M
Dividend Yield
―
Average Volume (3M)
321.46K
Price to Earnings (P/E)
-5.8
Beta (1Y)
0.07
Revenue Growth
6353.01%
EPS Growth
84.80%
Country
US
Employees
69
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Precision BioSciences Business Overview & Revenue Model

Company Description

Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome...

How the Company Makes Money

Precision BioSciences primarily generates revenue through collaboration-related arrangements rather than product sales (to the extent commercial products are not available or not material). Key revenue streams typically include: (1) upfront payments...

Precision BioSciences Financial Statement Overview

Summary

Overall fundamentals are weak due to persistently negative profitability and heavy cash burn. The income statement shows volatile revenue and deeply negative TTM net margin (~-86%), while cash flow is a major risk with TTM operating/free cash flow around -$51.8M. The balance sheet is comparatively healthier (very low debt of ~$1.7M vs. ~$51.8M equity), but ROE is materially negative (~-58%), reflecting ongoing losses.

Income Statement

28Negative

Balance Sheet

62Positive

Cash Flow

22Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue45.04M34.26M68.70M48.73M25.10M115.53M
Gross Profit44.46M34.26M68.70M48.73M25.10M115.53M
EBITDA-48.81M-42.43M13.53M-32.04M-62.79M-20.27M
Net Income-38.55M-45.72M7.17M-61.32M-111.64M-30.60M
Balance Sheet
Total Assets120.38M154.42M136.39M159.78M238.17M211.50M
Cash, Cash Equivalents and Short-Term Investments81.85M115.58M86.31M116.68M189.58M143.66M
Total Debt27.72M28.81M30.05M31.27M24.96M9.11M
Total Liabilities68.60M62.17M80.00M140.92M177.74M120.33M
Stockholders Equity51.77M92.25M56.39M18.86M60.43M91.17M
Cash Flow
Free Cash Flow-51.81M-65.93M-58.70M-86.39M-49.07M-16.66M
Operating Cash Flow-51.76M-65.84M-58.45M-84.11M-45.75M-10.85M
Investing Cash Flow-638.00K-634.00K-215.00K5.83M-3.32M-5.80M
Financing Cash Flow89.22M95.16M50.45M5.39M94.98M70.52M

Precision BioSciences Technical Analysis

Technical Analysis SentimentNegative
Last Price7.10

Price Trends

50DMA7.00Positive
100DMA7.43Negative
200DMA6.81Positive

Market Momentum

MACD0.22Positive
RSI45.19Neutral
STOCH4.28Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DTIL, the sentiment is Negative. The current price of 7.10 is below the 20-day moving average (MA) of 7.82, above the 50-day MA of 7.00, and above the 200-day MA of 6.81, indicating a neutral trend. The MACD of 0.22 indicates Positive momentum. The RSI at 45.19 is Neutral, neither overbought nor oversold. The STOCH value of 4.28 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DTIL.

Precision BioSciences Risk Analysis

Precision BioSciences disclosed 75 risk factors in its most recent earnings report. Precision BioSciences reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk
1.Our failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of our common stock.Q4, 2023

Precision BioSciences Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DTIL against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
DTILDTIL54Neutral$198.34M-5.77-58.09%―6353.01%84.80%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ACETACET49Neutral$26.03M-0.29-69.71%――57.60%
CTMXCTMX46Neutral$409.85M-4.17-33.97%―-87.66%-210.45%
IMAIMA44Neutral$48.58M-1.23-32.90%――61.67%
ACRVACRV42Neutral$66.94M-0.85-80.87%――14.08%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%DTILCTMXACETIMAACRVDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DTIL and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DTILPrecision Biosciences7.102.1042.00%
CTMXCytomX Therapeutics Inc.1.88-2.00-51.55%
ACETAdicet Bio Inc2.50-7.14-74.06%
IMAImagenebio, Inc.3.81-3.30-46.41%
ACRVAcrivon Therapeutics, Inc.1.56-0.74-32.17%

Precision BioSciences Corporate Events

Private Placements and Financing

Precision BioSciences Expands Capital Resources Through Public Offering

Positive
Nov 9, 2026

On November 5, 2026, Precision BioSciences entered into an underwriting agreement for an offering of 10,235,077 common shares at $7.75 each and pre-funded warrants to purchase up to 5,893,964 shares at $7.749995 per warrant. The financing expanded th...

Private Placements and Financing

Precision BioSciences Prices $125 Million Public Offering

Positive
Nov 6, 2026

On November 5, 2026, Precision BioSciences entered an underwriting agreement and priced an offering of 10,235,077 common shares at $7.75 each and pre-funded warrants for up to 5,893,964 shares at $7.749995 each. The company expected approximately $12...

Product-Related Announcements

Precision BioSciences Reports Positive Clinical Trial Updates

Positive
Nov 5, 2026

On November 5, 2026, Precision BioSciences reported new and updated preliminary Phase 1 ELIMINATE-B data for PBGENE-HBV, with 25 patients receiving 59 administrations across four dose levels by September 28, 2026. At the selected 0.4 mg/kg dose, all...

Business Operations and StrategyProduct-Related Announcements

Precision BioSciences Begins First DMD Gene-Editing Trial

Positive
Aug 24, 2026

On August 24, 2026, Precision BioSciences announced that it had dosed the first patient in its Phase 1/2 FUNCTION-DMD clinical trial of PBGENE-DMD at Arkansas Children’s Hospital, marking the first clinical gene-editing program for Duchenne muscular...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026